NRC FORM 374
(7-94)

U.S. NUCLEAR REGULATORY COMMISSION



# MATERIALS LICENSE

Amendment No. 72

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 39, 40, and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

301805

| Licensee | |
|---|---|
| 1. St. Vincent Hospital & Health Care Center<br>2. 2001 West 86th Street<br>Indianapolis, IN 46240-0970 | In accordance with the letter dated August 27, 1996<br>3. License Number 13-00133-02 is amended in its entirety to read as follows:<br>4. Expiration Date April 30, 2002<br>5. Docket or Reference No. 030-01579 |

| 6. Byproduct, Source, and/or Special Nuclear Material | 7. Chemical and/or Physical Form | 8. Maximum Amount that Licensee May Possess at Any One Time Under This License |
|---|---|---|
| A. Any byproduct material identified in 10 CFR 35.100 | A. Any radiopharmaceutical identified in 10 CFR 35.100 | A. As needed |
| B. Any byproduct material identified in 10 CFR 35.200 | B. Any radiopharmaceutical identified in 10 CFR 35.200 | B. As needed |
| C. Any byproduct material identified in 10 CFR 35.300 | C. Any radiopharmaceutical identified in 10 CFR 35.300 | C. As needed (Not to exceed 9 curies of iodine-131) |
| D. Any byproduct material identified in 10 CFR 35.400 | D. Any brachytherapy source identified in 10 CFR 35.400 | D. As needed |
| E. Any byproduct material identified in 10 CFR 31.11 | E. Prepackaged Kits | E. As needed |

280016

**MATERIALS LICENSE**
**SUPPLEMENTARY SHEET**

License Number: 13-00133-02
Docket or Reference Number: 030-01579
Amendment No. 72

| 6. Byproduct, source, and/or special nuclear material | 7. Chemical and/or physical form | 8. Maximum amount that licensee may possess at any one time under this license |
|---|---|---|
| F. Iridium-192 | F. Precut brachytherapy source wires (Manufactured, labeled, packaged, and distributed in accordance with a specific license issued pursuant to Section 32.74 of 10 CFR Part 32 or a specific license issued to a manufacturer by an Agreement State pursuant to equivalent State regulations). | F. 1.0 curie |
| G. Iridium-192 | G. Sealed sources (Byk Mallinckrodt Model CI L BV) | G. 2 sources, 1 source not to exceed 444 terabecquerels (Tbq) (12 curies (Ci)), and 1 source not to exceed 370 Tbq (10 Ci). |

9. Authorized Use:

A. Medical use described in 10 CFR 35.100.

B. Medical use described in 10 CFR 35.200.

C. Medical use described in 10 CFR 35.300.

D. Medical use described in 10 CFR 35.400.

E. In vitro studies.

F. To be used for interstitial and intracavitary treatment of cancer.

**MATERIALS LICENSE**
**SUPPLEMENTARY SHEET**

License Number: 13-00133-02
Docket or Reference Number: 030-01579
Amendment No. 72

G. One source to be used in a Nucletron-Oldelft Corporation Micro Selectron HDR remote afterloading brachytherapy device for interstitial, intraluminal, and intracavitary radiotherapy in humans. The source activity may not exceed 370 Tbq (10 Ci) at the time of installation. One source in its shipping container for source replacement.

CONDITIONS

10. Location of Use: 2001 West 86th Street, Indianapolis, Indiana.

11. Radiation Safety Officer: Robert C. Gregory, M.S.

12. Licensed material listed in Item 6 above is only authorized for use by, or under the supervision of, the following individuals for the materials and uses indicated:

| Authorized Users | Material and Use |
|---|---|
| A. Edward C. Wheeler, M.D. | 10 CFR 35.100, 35.200, 35.300, 35.400, 31.11, iridium-192 wire, and iridium-192 in remote afterloading brachytherapy unit. |
| B. Daniel R. Elliott, M.D. | 10 CFR 35.100, 35.200, 35.300, 35.400, 31.11, iridium-192 wire, and iridium-192 in remote afterloading brachytherapy unit. |
| C. John L. Horvath, M.D. | 10 CFR 35.100, 35.200, 35.400, 31.11, iridium-192 wire, and iridium-192 in remote afterloading brachytherapy unit, colloidal phosphorus-32 and strontium-89 for therapy. |
| D. John D. Slack, M.D. | 10 CFR 35.200, limited to cardiovascular clinical procedures. |
| E. Peter D. Arfken, M.D. | 10 CFR 35.100, 35.200, and 35.300. |
| F. John A. Morton, M.D. | 10 CFR 35.100, 35.200, 35.300 and 31.11. |
| G. Thomas James Linnemeier, M.D. | 10 CFR 35.200, limited to cardiovascular clinical procedures. |
| H. Ronald J. Landin, M.D. | 10 CFR 35.200, limited to cardiovascular clinical procedures. |

**MATERIALS LICENSE**
**SUPPLEMENTARY SHEET**

License Number: 13-00133-02
Docket or Reference Number: 030-01579
Amendment No. 72

| Authorized Users | | Material and Use |
|---|---|---|
| I. | Charles M. Orr, M.D. | 10 CFR 35.200, limited to cardiovascular clinical procedures. |
| J. | Michael L. Smith, M.D. | 10 CFR 35.200, limited to cardiovascular clinical procedures. |
| K. | Rosalind H. Webb, M.D. | 10 CFR 35.100, 35.200 and 35.300. |
| L. | Frank W. Peyton, Jr., M.D. | 10 CFR 35.400, phosphorus-32 and strontium-89 for therapy, iridium-192 wire, and iridium-192 in remote afterloading brachytherapy unit. |
| M. | Martin Richard See, M.D. | 10 CFR 35.100 and 35.200. |
| N. | Michael W. Ball, M.D. | 10 CFR 35.200, limited to cardiovascular clinical procedures. |
| O. | Edward R. Bartley, M.D. | 10 CFR 35.100 and 35.200. |
| P. | Jeffrey I. Reider, M.D. | 10 CFR 35.100 and 35.200. |
| Q. | Homer F. Beltz, M.D. | 10 CFR 35.100 and 35.200. |
| R. | Mitchell A. Russ, M.D. | 10 CFR 35.100 and 35.200. |
| S. | Richard T. Beeler, M.D. | 10 CFR 35.100, 35.200 and 35.300. |
| T. | Steven A. Fritsch, M.D. | 10 CFR 35.100 and 35.200. |
| U. | Vincent M. Bournique, M.D. | 10 CFR 35.200, limited to cardiovascular clinical procedures. |
| V. | Charles P. Taliercio, M.D. | 10 CFR 35.200, limited to cardiovascular clinical procedures. |
| W. | Katharine L. Krol, M.D. | 10 CFR 35.100, 35.200, 35.300 and 35.500. |
| X. | Frank J. Pistoia, M.D. | 10 CFR 35.100 and 35.200. |
| Y. | Michael A. Kuharik, M.D. | 10 CFR 35.100 and 35.200. |
| Z. | Stanley S. Givens, M.D. | 10 CFR 35.300, 35.400 and iridium-192 in remote afterloading brachytherapy unit. |

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License Number
13-00133-02

Docket or Reference Number
030-01579

Amendment No. 72

| Authorized Users | Material and Use |
|---|---|
| AA. Christopher A. Leagre, M.D. | 10 CFR 35.300, 35.400 and iridium-192 in remote afterloading brachytherapy unit. |
| BB. Janalyn P. Ferguson, M.D. | 10 CFR 35.100 and 35.200. |
| CC. Jane S. Mitchell, M.D. | 10 CFR 35.100 and 35.200. |
| DD. Jack J. Moss, M.D. | 10 CFR 35.100 and 35.200. |
| EE. Lori J. Wells, M.D. | 10 CFR 35.100 and 35.200. |
| FF. Eric D. Elliott, M.D. | 10 CFR 35.100 and 35.200. |
| GG. Robert J. Rapoport, M.D. | 10 CFR 35.100 and 35.200. |
| HH. Joseph E. Steinmetz, M.D. | 10 CFR 35.200 (limited to cardiovascular clinical procedures). |
| II. David R. Schmidt, M.D. | 10 CFR 35.200 (limited to cardiovascular clinical procedures). |
| JJ. Mary M. Walsh, M.D. | 10 CFR 35.200 (limited to cardiovascular clinical procedures). |
| KK. Morton Tavel, M.D. | 10 CFR 35.200 (limited to cardiovascular clinical procedures). |
| LL. Daniel M. Gelfman, M.D. | 10 CFR 35.200 (limited to cardiovascular clinical procedures). |
| MM. Daniel Lips, M.D. | 10 CFR 35.200 (limited to cardiovascular clinical procedures). |
| NN. Gregory B. Elsner, M.D. | 10 CFR 35.200 (limited to cardiovascular clinical procedures). |
| OO. Fred Spottsville, M.D. | 10 CFR 35.200 (limited to cardiovascular clinical procedures). |
| PP. Jeffery L. Haist, M.D. | 10 CFR 35.200 (limited to cardiovascular clinical procedures). |
| QQ. Howard J. Cheshire, M.D. | 10 CFR 35.200 (limited to cardiovascular clinical procedures). |

**MATERIALS LICENSE**
**SUPPLEMENTARY SHEET**

License Number: 13-00133-02
Docket or Reference Number: 030-01579
Amendment No. 72

| Authorized Users | Material and Use |
|---|---|
| RR. Gary A. Frick, M.S., D.O. | 10 CFR 35.200 (limited to cardiovascular clinical procedures). |
| SS. Lawrence Poliner, M.D. | 10 CFR 35.200 (limited to cardiovascular clinical procedures). |

13. In addition to the possession limits in Item 8, the licensee shall further restrict the possession of licensed material to quantities below the minimum limit specified in 10 CFR 30.35(d) for establishing decommissioning financial assurance.

14. In lieu of 10 CFR 35.404(a), immediately after retracting the source from the patient into its shielded position in the remote afterloading device, a radiation survey shall be made of the patient and the remote afterloading device with a portable radiation detection survey instrument to conform that the source has been removed from the patient. Records of the survey shall be maintained in lieu of the record required in 10 CFR 35.404(b).

15. In lieu of the source inventory required in 10 CFR 35.406, the licensee shall:

    A. Promptly determine that all sources have returned to the safe, shielded position at the conclusion of each remote afterloading brachytherapy procedure.

    B. Promptly make a survey of the area of use to confirm that no sources have been misplaced.

    C. Make a record of the survey including the survey instrument used, dose rate expressed in mrem/hr ($\mu$Sieverts/hr), time, date and name of the individual making the survey.

    D. Retain the record of the survey in lieu of the record required in 10 CFR 35.406(d).

16. Prior to initiation of a treatment program, and subsequent to each source exchange using the Nucletron Oldelft Micro Selectron HDR remote afterloading brachytherapy device, radiation surveys and tests shall be performed in accordance with the following:

    A. A radiation survey shall be made of:

        (1) The irradiator source housing, with the source in the shielded position. The maximum radiation levels at 100 centimeters from the surface of the main source safe shall not exceed 0.25 milliroentgen per hour.

(2) All areas adjacent to the treatment room with the source in the "irradiation" position. The survey shall clearly establish:

(a) That radiation levels in restricted areas are not likely to cause personnel exposure in excess of the limits specified in 10 CFR 20.1201.

(b) That radiation levels in unrestricted areas do not exceed the limits specified in 10 CFR 20.1301.

17. The following shall be performed only by manufacturer's representatives or persons specifically authorized by the Commission or an Agreement State to perform such services:

A. Installation and replacement of the sealed sources contained in the afterloading brachytherapy device(s).

B. Any maintenance or repair operations on the remote afterloading brachytherapy unit(s) listed in Item 9., Subitem G involving work on the source safe, the source drive unit, or other mechanism that could expose the source, reduce the shielding around the source, or compromise the safety of the unit and result in increased radiation levels.

18. A. Access to the rooms housing the Nucletron Oldelft Micro Selectron HDR remote afterloading brachytherapy device shall be controlled by a door at each entrance.

B. The entrance to the irradiation room shall be equipped with an electrical interlock system that will cause the source to return to the shielded position immediately upon opening of the entrance door. The interlock system shall be connected in such a manner that the source cannot be placed in the irradiation position until the entrance door is closed and the source "on-off" control is reset at the control panel.

C. Electrical interlocks on the entrance door to the irradiator room shall be tested for proper operation at least once each day of use.

D. In the event of malfunction of the door interlock, the irradiation device shall be locked in the "off" position and not used, except as may be necessary for repair or replacement of the interlock system, until the interlock system is shown to be functioning properly.

**MATERIALS LICENSE**
**SUPPLEMENTARY SHEET**

License Number: 13-00133-02
Docket or Reference Number: 030-01579
Amendment No. 72

19. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below, except for minor changes in the medical use radiation safety procedures as provided in 10 CFR 35.31. The Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.

A. Application dated March 24, 1992; and

B. Letter dated October 19, 1995.

FOR THE U.S. NUCLEAR REGULATORY COMMISSION

Date 9/17/96

By Michael L. Vick
Nuclear Materials Licensing Branch, Region III

BETWEEN:

License Fee Management Branch, ARM
and
Regional Licensing Sections

(FOR LFMS USE)
INFORMATION FROM LTS

Program Code: 02230
Status Code: 0
Fee Category: 7C 2B
Exp. Date: 20020430
Fee Comments: CODE 21
Decom Fin Assur Reqd: N

21
S2

LICENSE FEE TRANSMITTAL

A. REGION

1. APPLICATION ATTACHED
   Applicant/Licensee: ST. VINCENT HOSP. & HLTH. CARE CNTR
   Received Date: 960905
   Docket No: 3001579
   Control No.: 301805
   License No.: 13-00133-02
   Action Type: Amendment

2. FEE ATTACHED
   Amount: 0
   Check No.: 0

3. COMMENTS

Signed D. Hersey
Date 9-26-96

B. LICENSE FEE MANAGEMENT BRANCH (Check when milestone 03 is entered / ✓)

1. Fee Category and Amount: 7C #440

2. Correct Fee Paid. Application may be processed for:
   Amendment ✓
   Renewal
   License

3. OTHER

Signed DC
Date 10/7/96

OCT 15 1996

Log Sept 7 III
Remitter
Check No. 468960
Amount #440
Fee Category 7C 2B
Type of Fee AMD
Date Check Rec'd 10/7/96
Date Completed
By: DC

1996 SEP 13 AM 10:45

St. Vincent
Hospitals and
Health Services

2001 West 86th Street
P.O. Box 40970
Indianapolis, Indiana
46240-0970
317-338-2345

August 27, 1996

U.S. Nuclear Regulatory Commission
Region III
Materials Licensing Branch
801 Warrenville Road
Lisle, IL 60532-4351

RE: Amendment to Medical Materials License #13-00133-02

Gentlemen:

We are writing to have our License amended to include the following:

1) Peter D. Arfken, M.D. - as an authorized user for material in 10 CFR 35.300 to include Iodine-131 for thyroid carcinoma therapy. USNRC Supplements A & B are enclosed. Dr. Arfken is currently licensed under the above referenced License 13-00133-02. Refer to Amendment 71, #12.E.

2) John A. Morton, M.D. - as an authorized user for material in 10 CFR 35.300 to include Iodine-131 for hyperthyroid therapy and thyroid carcinoma therapy. USNRC Supplements A & B are enclosed. Dr. Morton is currently licensed under the above referenced License 13-00133-02. Refer to Amendment 71, #12.F.

3) Joseph E. Steinmetz, M.D. - as an authorized user for material in 10 CFR 35.200 limited to cardiovascular clinical procedures.

4) David R. Schmidt, M.D. - as an authorized user for material in 10 CFR 35.200 limited to cardiovascular clinical procedures.

5) Mary M. Walsh, M.D. - as an authorized user for material in 10 CFR 35.200 limited to cardiovascular clinical procedures.

6) Morton Tavel, M.D. - as an authorized user for material in 10 CFR 35.200 limited to cardiovascular clinical procedures.

ST. VINCENT
CORE VALUES:

Respect
A high regard for the worth of each person

Quality Service
Excellence in duty or work performed for others

Advocacy for the Poor
Supporting the cause of those who lack resources for a reasonable quality of life

Simplicity
Honesty, integrity and straightforwardness

Inventiveness to Infinity
Boundless creativity

Member of the
DAUGHTERS OF CHARITY
NATIONAL HEALTH SYSTEM



PM: 9-3-96

7) Daniel M. Gelfman, M.D. - as an authorized user for material in 10 CFR 35.200 limited to cardiovascular clinical procedures.

8) Daniel Lips, M.D. - as an authorized user for material in 10 CFR 35.200 limited to cardiovascular clinical procedures.

9) Gregory B. Elsner, M.D. - as an authorized user for material in 10 CFR 35.200 limited to cardiovascular clinical procedures.

The physicians listed from 3 thru 9 are members of Northside Cardiology, P.C. and are licensed under **NRC License # 13-24359-01** which expires 12/31/99. A copy of their license is attached.

10) Fred Spottsville, M.D. - as an authorized user for material in 10 CFR 35.200 limited to cardiovascular clinical procedures.

11) Jeffery L. Haist, M.D. - as an authorized user for material in 10 CFR 35.200 limited to cardiovascular clinical procedures.

12) Howard J. Cheshire, M.D. - as an authorized user for material in 10 CFR 35.200 limited to cardiovascular clinical procedures.

13) Gary A. Frick, M.S., D.O. - as an authorized user for material in 10 CFR 35.200 limited to cardiovascular clinical procedures.

14) Lawrence Poliner, M.D. - as an authorized user for material in 10 CFR 35.200 limited to cardiovascular clinical procedures.

The physicians listed from 10 thru 14 are members of Nasser, Smith & Pinkerton Cardiology, Inc. and are licensed under **NRC License # 13-19923-01** which expires 08/31/97.

Notification was provided on March 25, 1996 that the above named cardiologists (3 thru 14) were approved by the St. Vincent Hospital Radiation Safety Committee as authorized users for material in 10 CFR 35.200 limited to cardiovascular clinical procedures.

If you have any questions concerning this request, please contact me at (317) 338-2246.

Respectfully submitted,

Robert C. Gregory

Robert C. Gregory, M.S., R.S.O.

/cad

Enclosures

EXHIBIT 2

SUPPLEMENT A

SUPPLEMENT — U.S. NUCLEAR REGULATORY COMMISSION

## TRAINING AND EXPERIENCE
## AUTHORIZED USER OR RADIATION SAFETY OFFICER

| 1. NAME OF PROPOSED AUTHORIZED USER OR RADIATION SAFETY OFFICER | 2. FOR PHYSICIANS, STATE OR TERRITORY WHERE LICENSED |
|---|---|
| Peter D. Arfken, M.D. | Indiana |

**3. CERTIFICATION**

| SPECIALTY BOARD<br>A | CATEGORY<br>B | MONTH AND YEAR CERTIFIED<br>C |
|---|---|---|
| Radiology, Diagnostic<br>American Board of Radiology | Diagnostic | June, 1981 |

**4. TRAINING RECEIVED IN BASIC RADIOISOTOPE HANDLING TECHNIQUES**

| FIELD OF TRAINING<br>A | LOCATION AND DATE(S) OF TRAINING<br>B | TYPE AND LENGTH OF TRAINING | |
|---|---|---|---|
| | | CLOCK HOURS IN LECTURE OR LABORATORY | CLOCK HOURS OF SUPERVISED ON-THE-JOB EXPERIENCE |
| a. RADIATION PHYSICS AND INSTRUMENTATION | | | |
| b. RADIATION PROTECTION | | | |
| c. MATHEMATICS PERTAINING TO THE USE AND MEASUREMENT OF RADIOACTIVITY | | | |
| d. RADIATION BIOLOGY | | | |
| e. RADIOPHARMACEUTICAL CHEMISTRY | | | |

**5. EXPERIENCE WITH RADIATION.** *(Actual use of Radioisotopes or Equivalent Experience)*

| ISOTOPE | mCi USED AT ONE TIME | LOCATION | CLOCK HOURS | TYPE OF USE |
|---|---|---|---|---|
| | | | | |

EXHIBIT 3

SUPPLEMENT B

**SUPPLEMENT** — **U. S. NUCLEAR REGULATORY COMMISSION**

## PRECEPTOR STATEMENT

*Supplement B must be completed by the applicant physician's preceptor. If more than one preceptor is necessary to document experience, obtain a separate statement from each.*

1. PROPOSED PHYSICIAN USER'S NAME AND ADDRESS

FULL NAME: Peter D. Arfken, M.D.

STREET ADDRESS: St. Vincent Hospitals & Health Services
2001 West 86th Street

CITY: Indianapolis | STATE: IN | ZIP CODE: 46240-0970

**KEY TO COLUMN C**

**PERSONAL PARTICIPATION SHOULD CONSIST OF:**

1-Supervised examination of patients to determine the suitability for radioisotope diagnosis and/or treatment and recommendation for prescribed dosage.

2-Collaboration in dose calibration and actual administration of dose to the patient including calculation of the radiation dose, related measurements and plotting of data.

3-Adequate period of training to enable physician to manage radioactive patients and follow patients through diagnosis and/or course of treatment.

2. CLINICAL TRAINING AND EXPERIENCE OF ABOVE NAMED PHYSICIAN

| ISOTOPE A | CONDITIONS DIAGNOSED OR TREATED B | NUMBER OF CASES INVOLVING PERSONAL PARTICIPATION C | COMMENTS (Additional information or comments may be submitted in duplicate on separate sheets.) D |
|---|---|---|---|
| | Thyroid scan | | |
| | Thyroid uptake | | |
| | Lung perfusion scan | | |
| | Xenon ventilation study | | |
| | Aerosol ventilation scan | | |
| | Renal flow scan | | |
| | Brain scan | | |
| | Liver/spleen scan | | |
| | Bone scan | | |
| | Gastroesophageal study | | |
| | LeVeen shunt study | | |
| | Cystogram | | |
| | Dacryocystogram | | |
| | Cardiac perfusion scan. | | |
| | Cardiac stress ventriculogram | | |
| | Cardiac rest ventriculogram | | |
| | Gallium scan | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |

PROPOSED PHYSICIAN USER
Peter D. Arfken, M.D.

**PRECEPTOR STATEMENT** *(Continued)*

**2. CLINICAL TRAINING AND EXPERIENCE OF ABOVE NAMED PHYSICIAN** *(Continued)*

| ISOTOPE<br>A | CONDITIONS DIAGNOSED OR TREATED<br>B | NUMBER OF CASES INVOLVING PERSONAL PARTICIPATION<br>C | COMMENTS<br>*(Additional information or comments may be submitted in duplicate on separate sheets.)*<br>D |
|---|---|---|---|
| P-32 (Soluble) | TREATMENT OF POLYCYTHEMIA VERA, LEUKEMIA, AND BONE METASTASES | | |
| P-32 (Colloidal) | INTRACAVITARY TREATMENT | | |
| I-131 | TREATMENT OF THYROID CARCINOMA | 3 | |
| | TREATMENT OF HYPERTHYROIDISM | | |
| Au-198 | INTRACAVITARY TREATMENT | | |
| Co-60 or Cs-137 | INTERSTITIAL TREATMENT | | |
| | INTRACAVITARY TREATMENT | | |
| I-125 or Ir-192 | INTERSTITIAL TREATMENT | | |
| Co-60 or Cs-137 | TELETHERAPY TREATMENT | | |
| Sr-90 | TREATMENT OF EYE DISEASE | | |
| | RADIOPHARMACEUTICAL PREPARATION | | |
| Mo-99/ Tc-99m | GENERATOR | | |
| Sn-113/ In-113m | GENERATOR | | |
| Tc-99m | REAGENT KITS | | |
| Other | | | |

**3. DATES AND TOTAL NUMBER OF HOURS RECEIVED IN CLINICAL RADIOISOTOPE TRAINING**

| LOCATION | DATES | CLOCK HOURS OF EXPERIENCE |
|---|---|---|
| | | |

**4. THE TRAINING AND EXPERIENCE INDICATED ABOVE WAS OBTAINED UNDER THE SUPERVISION OF:**

a. NAME OF SUPERVISOR
Rosalind H. Webb, M.D.

b. NAME OF INSTITUTION
St. Vincent Hospital & Health Services

c. MAILING ADDRESS
2001 West 86th Street

d. CITY
Indianapolis, IN 46240-0970

5. MATERIALS LICENSE NUMBER(S)
13-00133-02

5. PRECEPTOR'S SIGNATURE
Rosalind H Webb MD

7. PRECEPTOR'S NAME *(Please type or print)*
Rosalind H. Webb, M.D.

8. DATE
8/21/96

**ST VINCENT HOSPITAL**
**INDIANAPOLIS, INDIANA**
**Nuclear Medicine Department**

Peter Arfken, MD

THYROID CARCINOMA THERAPY

| PATIENT NAME | M# | DATE | AMOUNT |
|---|---|---|---|
| [redacted] | [redacted] | [redacted] | [redacted] |

EXHIBIT 2

SUPPLEMENT A

SUPPLEMENT — U.S. NUCLEAR REGULATORY COMMISSION

## TRAINING AND EXPERIENCE
## AUTHORIZED USER OR RADIATION SAFETY OFFICER

| 1. NAME OF PROPOSED AUTHORIZED USER OR RADIATION SAFETY OFFICER | 2. FOR PHYSICIANS, STATE OR TERRITORY WHERE LICENSED |
|---|---|
| John A. Morton, M.D. | Indiana |

**3. CERTIFICATION**

| SPECIALTY BOARD<br>A | CATEGORY<br>B | MONTH AND YEAR CERTIFIED<br>C |
|---|---|---|
| Radiology, Diagnostic<br>American Board of<br>Radiology | Diagnostic | June, 1982 |

**4. TRAINING RECEIVED IN BASIC RADIOISOTOPE HANDLING TECHNIQUES**

| FIELD OF TRAINING<br>A | LOCATION AND DATE(S) OF TRAINING<br>B | TYPE AND LENGTH OF TRAINING | |
|---|---|---|---|
| | | CLOCK HOURS IN LECTURE OR LABORATORY | CLOCK HOURS OF SUPERVISED ON-THE-JOB EXPERIENCE |
| a. RADIATION PHYSICS AND INSTRUMENTATION | | | |
| b. RADIATION PROTECTION | | | |
| c. MATHEMATICS PERTAINING TO THE USE AND MEASUREMENT OF RADIOACTIVITY | | | |
| d. RADIATION BIOLOGY | | | |
| e. RADIOPHARMACEUTICAL CHEMISTRY | | | |

**5. EXPERIENCE WITH RADIA[illegible]ON.** *(Actual use of Radioisotopes or Equivalent Experience)*

| ISOTOPE | mCi USED AT ONE TIME | [illegible]ATION | CLOCK HOURS | TYPE OF USE |
|---|---|---|---|---|
| | | | | |

EXHIBIT 3

SUPPLEMENT B

SUPPLEMENT — U. S. NUCLEAR REGULATORY COMMISSION

## PRECEPTOR STATEMENT

*Supplement B must be completed by the applicant physician's preceptor. If more than one preceptor is necessary to document experience, obtain a separate statement from each.*

1. PROPOSED PHYSICIAN USER'S NAME AND ADDRESS

FULL NAME: John A. Morton, M.D.

STREET ADDRESS: St. Vincent Hospitals & Health Services
2001 West 86th Street

CITY: Indianapolis | STATE: IN | ZIP CODE: 46240-0970

**KEY TO COLUMN C**

**PERSONAL PARTICIPATION SHOULD CONSIST OF:**

1-Supervised examination of patients to determine the suitability for radioisotope diagnosis and/or treatment and recommendation for prescribed dosage.

2-Collaboration in dose calibration and actual administration of dose to the patient including calculation of the radiation dose, related measurements and plotting of data.

3-Adequate period of training to enable physician to manage radioactive patients and follow patients through diagnosis and/or course of treatment.

2. CLINICAL TRAINING AND EXPERIENCE OF ABOVE NAMED PHYSICIAN

| ISOTOPE A | CONDITIONS DIAGNOSED OR TREATED B | NUMBER OF CASES INVOLVING PERSONAL PARTICIPATION C | COMMENTS (Additional information or comments may be submitted in duplicate on separate sheets.) D |
|---|---|---|---|
| | Thyroid scan | | |
| | Thyroid uptake | | |
| | Lung perfusion scan | | |
| | Xenon ventilation study | | |
| | Aerosol ventilation scan | | |
| | Renal flow scan | | |
| | Brain scan | | |
| | Liver/spleen scan | | |
| | Bone scan | | |
| | Gastroesophageal study | | |
| | LeVeen shunt study | | |
| | Cystogram | | |
| | Dacryocystogram | | |
| | Cardiac perfusion scan. | | |
| | Cardiac stress ventriculogram | | |
| | Cardiac rest ventriculogram | | |
| | Gallium scan | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |

PROPOSED PHYSICIAN USER
John A. Morton, M.D.

## PRECEPTOR STATEMENT (Continued)

### 2. CLINICAL TRAINING AND EXPERIENCE OF ABOVE NAMED PHYSICIAN (Continued)

| ISOTOPE<br>A | CONDITIONS DIAGNOSED OR TREATED<br>B | NUMBER OF CASES INVOLVING PERSONAL PARTICIPATION<br>C | COMMENTS (Additional information or comments may be submitted in duplicate on separate sheets.)<br>D |
|---|---|---|---|
| P-32 (Soluble) | TREATMENT OF POLYCYTHEMIA VERA, LEUKEMIA, AND BONE METASTASES | | |
| P-32 (Colloidal) | INTRACAVITARY TREATMENT | | |
| I-131 | TREATMENT OF THYROID CARCINOMA | 3 | |
| | TREATMENT OF HYPERTHYROIDISM | 10 | |
| Au-198 | INTRACAVITARY TREATMENT | | |
| Co-60 or Cs-137 | INTERSTITIAL TREATMENT | | |
| | INTRACAVITARY TREATMENT | | |
| I-125 or Ir-192 | INTERSTITIAL TREATMENT | | |
| Co-60 or Cs-137 | TELETHERAPY TREATMENT | | |
| Sr-90 | TREATMENT OF EYE DISEASE | | |
| | RADIOPHARMACEUTICAL PREPARATION | | |
| Mo-99/ Tc-99m | GENERATOR | | |
| Sn-113/ In-113m | GENERATOR | | |
| Tc-99m | REAGENT KITS | | |
| Other | | | |

### 3. DATES AND TOTAL NUMBER OF HOURS RECEIVED IN CLINICAL RADIOISOTOPE TRAINING

| LOCATION | DATES | CLOCK HOURS OF EXPERIENCE |
|---|---|---|

### 4. THE TRAINING AND EXPERIENCE INDICATED ABOVE WAS OBTAINED UNDER THE SUPERVISION OF:

a. NAME OF SUPERVISOR
Rosalind H. Webb, M.D.

b. NAME OF INSTITUTION
St. Vincent Hospitals & Health Services

c. MAILING ADDRESS
2001 West 86th Street

d. CITY
Indianapolis, IN 46240-0970

e. MATERIALS LICENSE NUMBER(S)
13-00133-02

5. PRECEPTOR'S SIGNATURE
Rosaland H. Webb MD

7. PRECEPTOR'S NAME (Please type or print)
Rosalind H. Webb MD

8. DATE
8-21-96

**ST VINCENT HOSPITAL**
**INDIANAPOLIS, INDIANA**
**Nuclear Medicine Department**

John Morton, MD

HYPERTHYROID THERAPY

| PATIENT NAME | M# | DATE | AMOUNT |
|---|---|---|---|
| [redacted] | [redacted] | [redacted] | [redacted] |

THYROID CARCINOMA THERAPY

| | | | |
|---|---|---|---|
| [redacted] | [redacted] | [redacted] | [redacted] |

NRC FORM 374 (7-94)

U.S. NUCLEAR REGULATORY COMMISSION

PAGE 1 OF 2 PAGES

# MATERIALS LICENSE

Amendment No. 14

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 39, 40, and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

| Licensee | |
|---|---|
| 1. Northside Cardiology, P.C. | In accordance with letters dated August 8, 1995 and November 20, 1995 |
| 2. 8333 Naab Road, Suite 200<br>Indianapolis, IN 46260 | 3. License Number 13-24359-01 is amended in its entirety to read as follows: |
| | 4. Expiration Date December 31, 1999 |
| | 5. Docket or Reference No. 030-18523 |

| 6. Byproduct, Source, and/or Special Nuclear Material | 7. Chemical and/or Physical Form | 8. Maximum Amount that Licensee May Possess at Any One Time Under This License |
|---|---|---|
| A. Any byproduct material identified in 10 CFR 35.200 | A. Any radiopharmaceutical identified in 10 CFR 35.200 | A. As needed |

9. Authorized Use:

A. Medical use described in 10 CFR 35.200 limited to cardiovascular clinical procedures.

## CONDITIONS

10. Locations of Use: 13400 North Meridian, Suite 500, Carmel, Indiana; 3015 10th Street, Columbus, Indiana; and 8333 Naab Road, Suite 200, Indianapolis, Indiana.

11. Radiation Safety Officer: Ronald J. Landin, M.D.

12. Authorized Users:

A. Ronald J. Landin, M.D., for material in 10 CFR 35.200 limited to cardiovascular clinical procedures.

B. Thomas J. Linnemeier, M.D., for material in 10 CFR 35.200 limited to cardiovascular clinical procedures.

C. Martin See, M.D., for material in 10 CFR 35.200 limited to cardiovascular clinical procedures.

NRC Form 374A (5-84) U.S. NUCLEAR REGULATORY COMMISSION

MATERIALS LICENSE
SUPPLEMENTARY SHEET

PAGE 2 OF 2 PAGES

License number
13-24359-01

Docket or Reference number
030-18523

Amendment No. 14

D. Michael W. Ball, M.D., for material in 10 CFR 35.200 limited to cardiovascular clinical procedures.

E. Joseph E. Steinmetz, M.D., for material in 10 CFR 35.200 limited to cardiovascular clinical procedures.

F. David R. Schmidt, M.D., for material in 10 CFR 35.200 limited to cardiovascular clinical procedures.

G. Mary M. Walsh, M.D., for material in 10 CFR 35.200 limited to cardiovascular clinical procedures.

H. Morton Tavel, M.D., for material in 10 CFR 35.200 limited to cardiovascular clinical procedures.

I. Daniel M. Gelfman, M.D., for material in 10 CFR 35.200 limited to cardiovascular clinical procedures.

J. Daniel Lips, M.D., for material in 10 CFR 35.200 limited to cardiovascular clinical procedures.

K. Gregory B. Elsner, M.D., for material in 10 CFR 35.200 limited to cardiovascular clinical procedures.

13. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below, except for minor changes in the medical use radiation safety procedures as provided in 10 CFR 35.31. The Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.

A. Application dated September 13, 1994; and

B. Letters dated October 11, 1994, October 17, 1994, December 5, 1994, and February 6, 1995.

FOR THE U.S. NUCLEAR REGULATORY COMMISSION

Date 15 December 1995

By William L. Ruddell
Nuclear Materials Licensing Branch, Region III

NRC FORM 374 U.S. NUCLEAR REGULATORY COMMISSION PAGE 1 OF 3 PAGES

# MATERIALS LICENSE

Amendment No. 14

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 39, 40, and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

| Licensee | In accordance with application received April 28, 1995<br>3. License Number 13-19923-01 is amended in its entirety to read as follows: |
|---|---|
| Nasser, Smith & Pinkerton Cardiology, Inc.<br><br>8333 Naab Road, Suite 400<br>Indianapolis, IN 46260 | 4. Expiration Date August 31, 1997 |
| | 5. Docket or Reference No. 030-19538 |

| 6. Byproduct, Source, and/or Special Nuclear Material | 7. Chemical and/or Physical Form | 8. Maximum Amount that Licensee May Possess at Any One Time Under This License |
|---|---|---|
| A. Any byproduct material identified in 10 CFR 35.200 | A. Any radiopharmaceutical identified in 10 CFR 35.200 (excluding xenon-133) | A. As needed |

9. Authorized Use:

Medical use described in 10 CFR 35.200 limited to cardiovascular clinical procedures (excluding xenon-133).

## CONDITIONS

10. Locations of Use:

141 West 22nd Street, Suite 111
Anderson, Indiana

8333 Naab Road, Suite 400
Indianapolis, Indiana

1501 Chester Blvd.
Richmond, Indiana

1655 N. 7th Street
Terre Haute, Indiana

1614 Baldwin Avenue
Marion, Indiana

NRC Form 3744 (9-84) U.S. NUCLEAR REGULATORY COMMISSION

PAGE 2 OF 3 PAGES

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License number: 13-19923-01

Docket or Reference number: 030-19538

Amendment No. 14

11. Radiation Safety Officer: Jerry Bishop, CNMT

12. Authorized Users:

A. John D. Slack, M.D., for material in 10 CFR 35.200 limited to cardiovascular clinical procedures.

B. Charles M. Orr, M.D., for material in 10 CFR 35.200 limited to cardiovascular clinical procedures.

C. Michael L. Smith, M.D., for material in 10 CFR 35.200 limited to cardiovascular clinical procedures.

D. Charles P. Taliercio, M.D., for material in 10 CFR 35.200 limited to cardiovascular clinical procedures.

E. Fred Spottsville, M.D., for material in 10 CFR 35.200 limited to cardiovascular clinical procedures.

F. Jeffery L. Haist, M.D., for material in 10 CFR 35.200 limited to cardiovascular clinical procedures.

G. Howard J. Cheshire, M.D., for material in 10 CFR 35.200 limited to cardiovascular clinical procedures.

H. Gary A. Frick, M.S., D.O., for material in 10 CFR 35.200 limited to cardiovascular clinical procedures.

I. Lawrence Poliner, M.D., for material in 10 CFR 35.200 limited to cardiovascular clinical procedures.

13. The licensee shall maintain records of information important to safe and effective decommissioning at the location listed in Item 2. of this license per the provisions of 10 CFR 30.35(g) until this license is terminated by the Commission.

NRC FORM 577
(1-95)

U.S. NUCLEAR REGULATORY COMMISSION

# LICENSE FEE REQUIREMENTS

LICENSE FEE AND DEBT COLLECTION BRANCH
DIVISION OF ACCOUNTING AND FINANCE
OFFICE OF THE CONTROLLER
U.S. NUCLEAR REGULATORY COMMISSION
WASHINGTON, DC 20555-0001

ST. VINCENT HOSPITAL AND
HEALTH SERVICES
ATTN: ROBERT C. GREGORY, M.S.
P. O. BOX 40970
2001 WEST 86TH STREET
INDIANAPOLIS, INDIANA 46240-0970

**TYPE OF ACTION**

- ☐ NEW LICENSE
- ☐ RENEWAL OF LICENSE
- ☒ AMENDMENT TO LICENSE

REQUESTED DATE: 8-27-96

LICENSE NUMBER: 13-00133-02

CONTROL NUMBER: 301805

## I. APPLICATION FEE DUE

Your request for a licensing action is subject to the fee(s) in the category(ies) noted below in accordance with Section 170.31 of the enclosed Federal Register notice. Payment of the fee is required prior to the issuance of the license, renewal, or amendment.

| FEE CATEGORY | APPLICATION | RENEWAL | AMENDMENT |
|---|---|---|---|
| 7C | $ | $ | $ 440.00 |
| | $ | $ | $ |
| | $ | $ | $ |
| | $ | $ | $ |
| | $ | $ | $ |
| | $ | $ | $ |
| | $ | $ | $ |
| | $ | $ | $ |
| | $ | $ | $ |
| | $ | $ | $ |

| | |
|---|---|
| FEE(s) DUE | $ 440.00 |
| PAYMENT RECEIVED | $ 0.00 |
| AMOUNT DUE | $ 440.00 |

☒ Your request was received without the prescribed application fee.

☐ We received your Check No. _____ in the amount of $ _____. Payment of the additional fee noted above is required.

☐ Your request will increase the scope of your license program. Therefore, your request is subject to the application fee(s) noted above. Refer to Section 170.31 and Footnote 1(d)(2).

☐ Your license expired prior to the receipt of your application for renewal. Therefore, your request is subject to the application fee(s) noted above. Refer to Section 170.31 and Footnote 1(a).

MAKE PAYMENT OF THE FEE(S) TO THE U.S. NUCLEAR REGULATORY COMMISSION AND MAIL THE PAYMENT TO THE ADDRESS LISTED AT THE TOP OF THIS FORM. IF WE DO NOT RECEIVE A REPLY FROM YOU WITHIN 30 CALENDAR DAYS FROM THE DATE LISTED BELOW, WE SHALL ASSUME THAT YOU DO NOT WISH TO PURSUE YOUR APPLICATION AND WILL VOID THIS ACTION.

## II. FEE NOT REQUIRED

☐ Enclosed is Check No. _____ which accompanied your request. The fee is not required because:

☐ We received your Check No. _____ in payment of the fee.

☐ The Licensing staff has informed us that your request is to be considered as a continuation of your request dated _____, Control No. _____.

☐ Your request was combined, prior to review, with your _____ request, Control No. _____.

## III. CHECK RETURNED

☐ Enclosed is Check No. _____ which was returned to us by the bank for:

- ☐ INSUFFICIENT FUNDS
- ☐ ACCOUNT CLOSED
- ☐ OTHER

MAIL THE REPLACEMENT CHECK TO THE ADDRESS LISTED AT THE TOP OF THIS FORM AND REFERENCE THE ABOVE CONTROL NUMBER.

## IV. LICENSE ISSUED WITHOUT THE REQUIRED FEE

☐ License No. _____, Amendment No. _____, issued on _____ was issued without the required fee being collected. The fee required is noted in Section I of this form.

☐ The scope of your licensed program was increased. Therefore, your request is subject to the application fee(s) noted in Section 1 of this form. Refer to Section 170.31 and Footnote 1(d)(2).

☐ Because of the urgency of your request, the license was issued without remittance of the prescribed fee noted in Section 1 of this form.

| SIGNATURE – LICENSE FEE ANALYST | LFDCB | LFDCB |
|---|---|---|
| Shirley Crutchfield | SC | |
| SHIRLEY CRUTCHFIELD | 9/16/96 | |

Distribution: OC/DAF/RF
Pending Fee File OC/DAF/SF (LF-3.2.7)
LFARB R/F (2) Region 3

DATE: Sept. 16, 1996

NRC FORM 577 (1-95)

This form was electronically produced by Elite Federal Forms, Inc.

OCT 17 1996

Robert C. Gregory
Radiation Safety Officer
St. Vincent Hospital & Health
Care Center
2001 West 86th Street
Indianapolis, IN 46240-0970

Dear Mr. Gregory:

Enclosed is Amendment No. 72 to your NRC Material License No. 13-00133-02 in accordance with your request.

Please review the enclosed document carefully and be sure that you understand all conditions. If there are any errors or questions, please notify the U.S. Nuclear Regulatory Commission, Region III office at (630) 829-9887 so that we can provide appropriate corrections and answers.

Please be advised that your license expires at the end of the day, in the month, and year stated in the license. Unless your license has been terminated, you must conduct your program involving byproduct materials in accordance with the conditions of your NRC license, representations made in your license application, and NRC regulations. In particular, note that you must:

1. Operate in accordance with NRC regulations 10 CFR Part 19, "Notices, Instructions and Reports to Workers; Inspections," 10 CFR Part 20, "Standards for Protection Against Radiation," and other applicable regulations.

2. Notify NRC, in writing, within 30 days:

   a. When an authorized user or Radiation Safety Officer permanently discontinues performance of duties under the license or has a name change; or

   b. When the licensee's mailing address changes (no fee is required if the location of byproduct material remains the same).

3. In accordance with 10 CFR 30.36(b) and/or license condition, notify NRC, promptly, in writing, and request termination of the license when you decide to terminate all activities involving materials authorized under the license.

301805

4. Request and obtain a license amendment before you:

   a. Receive or use byproduct material for a clinical procedure permitted under Part 35 but not permitted by your license issued pursuant to this Part;

   b. Permit anyone, except individuals described in 10 CFR 35.13(b), to work as an authorized user under the license;

   c. Change Radiation Safety Officers;

   d. Order byproduct material in excess of the amount, or radionuclide, or form different than authorized on the license;

   e. Add or change the areas of use or address or addresses of use identified in the license application or on the license; or

   f. Change ownership of your organization.

5. Submit a complete renewal application with proper fee or termination request at least 30 days before the expiration date of your license. You will receive a reminder notice approximately 90 days before the expiration date. Possession of byproduct material after your license expires is a violation of NRC regulations. A license will not normally be renewed, except on a case-by-case basis, in instances where licensed material has never been possessed or used.

In addition, please note that NRC Form 313 requires the applicant, by his/her signature, to verify that the applicant understands that all statements contained in the application are true and correct to the best of the applicant's knowledge. The signatory for the application should be the licensee or certifying official rather than a consultant.

You will be periodically inspected by NRC. Failure to conduct your program in accordance with NRC regulations, license conditions, and representations made in your license application and supplemental correspondence with NRC will result in enforcement action against you. This could include issuance of a notice of violation, or imposition of a civil penalty, or an order suspending, modifying or revoking your license as specified in the General Policy and Procedures for NRC Enforcement Actions. Since serious consequences to employees and the public can result from failure to comply with NRC requirements,

prompt and vigorous enforcement action will be taken when dealing with licensees who do not achieve the necessary meticulous attention to detail and the high standard of compliance which NRC expects of its licensees.

Sincerely,

Original Signed By
Michael F. Weber
Nuclear Materials Licensing Branch

License No.: 13-00133-02
Docket No.: 030-01579

Enclosure: Amendment No. 72

DOCUMENT NAME: M:\03001579.CL6

To receive a copy of this document, indicate in the box: "C" = Copy without attachment/enclosure "E" = Copy with attachment/enclosure "N" = No copy

| OFFICE | DNMS/RIII | C | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| NAME | MWEBER:jaw | | | | | | | | |
| DATE | 09/17/96 | | | | | | | | |

OFFICIAL RECORD COPY

UNITED STATES
NUCLEAR REGULATORY COMMISSION
REGION III
801 WARRENVILLE ROAD
LISLE, ILLINOIS 60532-4351

September 6, 1996

Robert C. Gregory, M.S.
Radiation Safety Officer
St. Vincent Hospital & Health Care Center
2001 West 86th Street
Indianapolis, IN 46240-0970

SUBJECT: ACKNOWLEDGEMENT OF CORRESPONDENCE
(Letter Dated 08/27/96)

Dear Licensee:

In response to your request, we have completed the initial processing, which is an administrative review of your application for a(n):

__ New License  X Amendment  __ Renewal
__ Termination  __ Auth User (Amendment not required)  __ QMP Revision
__ Other _____

No administrative deficiencies were identified during this initial review. However, it should be noted that a technical review may identify omissions in the submitted information.

It appears that your request is routine (see 1-3 below, as applicable).

1. New and amendment actions are normally processed within 90 days, unless we find major deficiencies, or policy issues requiring central program office assistance.

2. Renewal actions are normally processed within 180 days, however, under timely filing (before expiration), you may continue to operate under your existing license.

3. Termination actions are normally processed within 90 days, unless confirmatory surveys following decontamination/decommissioning activities are involved.

A copy of your correspondence has been forwarded to our Licensing Fee and Debt Collection Branch (301/415-6097) for approval of the fee category and amount, if required.

If you have a compelling safety or business-related reason for requesting expedited review, please contact the Materials Licensing Branch at (630) 829-9887. We will try to complete your request as soon as practicable. Any correspondence about this request should reference the control number.

Nuclear Materials Support Branch

Mail Control No. 301805
License No. 13-00133-02